Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 733.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,461 shares of the medical equipment provider's stock after purchasing an additional 44,409 shares during the period. Hologic comprises approximately 1.0% of Lecap Asset Management Ltd.'s holdings, making the stock its 5th biggest holding. Lecap Asset Management Ltd.'s holdings in Hologic were worth $3,638,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of HOLX. Wolff Wiese Magana LLC acquired a new stake in Hologic during the third quarter worth approximately $25,000. General Partner Inc. acquired a new stake in shares of Hologic during the fourth quarter worth $26,000. Groupama Asset Managment grew its position in shares of Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 2,999 shares during the period. First Horizon Advisors Inc. increased its stake in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. Finally, Cromwell Holdings LLC lifted its position in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after buying an additional 416 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.88% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Royal Bank of Canada lowered their price target on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Mizuho dropped their price target on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a research report on Tuesday, November 5th. Evercore ISI decreased their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a report on Thursday, February 6th. JPMorgan Chase & Co. upped their price objective on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Finally, UBS Group increased their target price on Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Ten investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $85.77.

Hologic Stock Down 1.2 %

Shares of Hologic stock traded down $0.82 during trading hours on Tuesday, hitting $64.43. 1,149,312 shares of the company's stock traded hands, compared to its average volume of 2,550,244. Hologic, Inc. has a twelve month low of $63.62 and a twelve month high of $84.67. The company has a market cap of $14.54 billion, a PE ratio of 20.31, a PEG ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 3.03, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock has a 50 day simple moving average of $72.06 and a 200-day simple moving average of $77.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.